Eficacia de la terapia fotodinámica, fotobiomodulación, y corticoides en el tratamiento de liquen plano oral

Objetivo. Valorar la eficacia de la terapia fotodinámica y fotobioestimulación(PBM) en el tratamiento del liquen plano oral y comparar con corticoide tópicos Material y método: Estudio clínico randomizado. Se realizo en 60 pacientes con liquen plano oral Se asignaron al azar en 3 grupos: El grupo I de terapia fotodinámica , aplicación 1 vez por semana, totalizando 4 sesiones, y crema orabase ; grupo II Pacientes a los que se les aplica láser de baja intensidad y aplicación ambulatoria crema orabase. El grupo III: aplicación de laser inactivo y crema acetónido de triamcinolona orabase 0.1%. Se evalúo el dolor; escala de severidad de Thongprason calidad de vida oral OHIP14 y ansiedad y depresión de Hamilton .Se realizo periodo de seguimiento al mes y a los 3 meses. Resultados La muestra final se ha constituido con 59 pacientes (86,4% mujeres y 13,6% hombres), con edad media 60,7 años. El dolor disminuyó significativamente a través del tiempo, en todos los grupos; sin embargo el grupoIII la sintomatología recidivo en el periodo de seguimiento al mes y a los 3 meses . La calidad de vida OHIP 14 encontramos una mejora significativa en grupo Iy grupoII p<0.05 manteniéndose a los 3 meses. Respecto resolución de lesiones Thongprason al mes encontramos diferencias significativas grupoI -grupo III(p=0,032) y grupoII-grupIII (p=0,024) Conclusiones Estos hallazgos indican que la terapia fotodinámica como fotobiomodulación 1 vez por semana durante 4 semanas es efectiva son terapias seguras y no invasivas con la notable ventaja de que no tiene efectos adversos.Objective: To evaluate the efficacy of photodynamic therapy (PDT) and photobiomodulation (PBM) in the treatment of oral lichen planus (OLP) in comparison with the use of topical corticosteroids. Material and methods: Sixty patients with OLP were randomized to three groups: group 1 (photodynamic therapy applied once a week during 4 sessions, with orabase cream application); group 2 (low-power laser application with orabase cream); and group 3 (inactive laser application with triamcinolone acetonide orabase cream 0.1%). Pain was evaluated, with application of the Thongprasom severity score, the Oral Health Impact Profile-14 (OHIP-14) and the Hamilton anxiety and depression scale at one and three months of follow-up. Results: The final sample consisted of 59 patients (86.4% women and 13.6% men), with a mean age of 60.7 years. Pain decreased significantly over time in all groups, though the symptoms relapsed over follow-up at one and three months in group 3. Quality of life as assessed by the OHIP-14 score improved significantly in groups 1 and 2 (p<0.05), and this improvement was maintained after three months. Lesion resolution evaluated by the Thongprasom score at one month showed significant differences between groups 1 and 3 (p=0.032) and between groups 2 and 3 (p=0.024) Conclusions: The results obtained indicate that both photodynamic therapy and photobiomodulation once a week during four weeks are safe and noninvasive treatment options, with the important advantage of lacking adverse effects

Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial

Objective: To evaluate the efficacy of photodynamic therapy (PDT) and photobiomodulation (PBM) in the treatment of oral lichen planus (OLP) in comparison with the use of topical corticosteroids. Material and methods: Sixty patients with OLP were randomized to three groups: group 1 photodynamic therapy applied once a week for four sessions, with orabase cream; group 2 low-power laser application with orabase cream; and group 3 inactive laser with triamcinolone acetonide 0.1%. Patient pain was evaluated, and the Thongprasom severity score, the Oral Health Impact Profile-14 (OHIP-14), and the Hamilton anxiety and depression scale at one and three months of follow-up. (ClinicalTrials.gov Identifier: NCT05127083). Results: Pain decreased significantly over time in all groups, though the symptoms relapsed over follow-up at one and three months in group 3. The OHIP-14 score improved significantly in groups 1 and 2 (p p = 0.032) and between groups 2 and 3 (p = 0.024). Conclusions: Photodynamic therapy and photobiomodulation once a week for four weeks are safe and non-invasive treatment options, with the important advantage of lacking adverse effects. Further studies are needed to confirm it